These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24315317)

  • 21. Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese.
    Gu S; Sun Y; Han R; Wang L; Wang D; Wang J; Li X
    BMC Med Genet; 2014 Jul; 15():83. PubMed ID: 25030528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations.
    Lee SS; Lee SJ; Gwak J; Jung HJ; Thi-Le H; Song IS; Kim EY; Shin JG
    Ther Drug Monit; 2007 Aug; 29(4):455-9. PubMed ID: 17667801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYP2C19 genetic polymorphism in Saudi Arabians.
    Al-Jenoobi FI; Alkharfy KM; Alghamdi AM; Bagulb KM; Al-Mohizea AM; Al-Muhsen S; Halwani R; Parvez MK; Al-Dosari MS
    Basic Clin Pharmacol Toxicol; 2013 Jan; 112(1):50-4. PubMed ID: 22747643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High prevalence of CYP2C19*2 allele in Roma samples: study on Roma and Hungarian population samples with review of the literature.
    Sipeky C; Weber A; Szabo M; Melegh BI; Janicsek I; Tarlos G; Szabo I; Sumegi K; Melegh B
    Mol Biol Rep; 2013 Aug; 40(8):4727-35. PubMed ID: 23645039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.
    Chan MY; Tan K; Tan HC; Huan PT; Li B; Phua QH; Lee HK; Lee CH; Low A; Becker RC; Ong WC; Richards MA; Salim A; Tai ES; Koay E
    Pharmacogenomics; 2012 Apr; 13(5):533-42. PubMed ID: 22462746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese.
    Zhou Q; Yu XM; Lin HB; Wang L; Yun QZ; Hu SN; Wang DM
    Pharmacogenomics J; 2009 Dec; 9(6):380-94. PubMed ID: 19636337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.
    Sugimoto K; Uno T; Yamazaki H; Tateishi T
    Br J Clin Pharmacol; 2008 Mar; 65(3):437-9. PubMed ID: 18241287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).
    Pachkoria K; Lucena MI; Ruiz-Cabello F; Crespo E; Cabello MR; Andrade RJ;
    Br J Pharmacol; 2007 Mar; 150(6):808-15. PubMed ID: 17279092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Macedonia.
    Jakovski K; Nestorovska AK; Labacevski N; Dimovski AJ
    Pharmazie; 2013 Nov; 68(11):893-8. PubMed ID: 24380239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China.
    Chen L; Qin S; Xie J; Tang J; Yang L; Shen W; Zhao X; Du J; He G; Feng G; He L; Xing Q
    Pharmacogenomics; 2008 Jun; 9(6):691-702. PubMed ID: 18518848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic polymorphism of clopidogrel metabolism related gene
    Yuan XW; Yuan SY; Wu GX; Wu ZX; Guan ZY
    Hematology; 2022 Dec; 27(1):1056-1061. PubMed ID: 36112003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia.
    Griese EU; Ilett KF; Kitteringham NR; Eichelbaum M; Powell H; Spargo RM; LeSouef PN; Musk AW; Minchin RF
    Pharmacogenetics; 2001 Feb; 11(1):69-76. PubMed ID: 11207032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
    Liou YH; Lin CT; Wu YJ; Wu LS
    J Hum Genet; 2006; 51(10):857. PubMed ID: 16924387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
    Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
    Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allele and genotype frequency of CYP2C19 in a Tamilian population.
    Adithan C; Gerard N; Vasu S; Rosemary J; Shashindran CH; Krishnamoorthy R
    Br J Clin Pharmacol; 2003 Sep; 56(3):331-3. PubMed ID: 12919183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece.
    Ragia G; Arvanitidis KI; Tavridou A; Manolopoulos VG
    Pharmacogenomics; 2009 Jan; 10(1):43-9. PubMed ID: 19102714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip.
    Sameer AE; Amany GM; Abdela AA; Fadel SA
    Can J Clin Pharmacol; 2009; 16(1):e156-62. PubMed ID: 19193970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups.
    Luo HR; Aloumanis V; Lin KM; Gurwitz D; Wan YJ
    Am J Pharmacogenomics; 2004; 4(6):395-401. PubMed ID: 15651900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls.
    Babalola CP; Adejumo O; Ung D; Xu Z; Odetunde A; Kotila T; Falusi AG; Nagar S
    J Clin Pharm Ther; 2010 Aug; 35(4):471-7. PubMed ID: 20831548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.